[Effects of glypressin on the splanchnic and systemic circulation in patients with cirrhosis]. 1985

D Valla, and S S Lee, and R Moreau, and A Hadengue, and R Sayegh, and D Lebrec

Although not demonstrated in patients with cirrhosis, it is generally claimed that administration of vasopressin in the form of triglycyl-lysine-vasopressin (glypressin) may prevent untoward systemic effects of this former hormone. The aim of this study was to assess the effects of intravenous administration of 2 mg of glypressin on splanchnic and systemic hemodynamics in 9 patients with cirrhosis under stable circulatory conditions. One hour after the injection, the following statistically significant changes were observed as compared to the baseline values (m +/- SEM): wedged hepatic venous pressure, -9 +/- 2 p. 100; hepatic venous pressure gradient, -16 +/- 3 p. 100; azygos blood flow, -24 +/- 6 p. 100; heart rate, -16 +/- 3 p. 100; cardiac index, -23 +/- 2 p. 100; systemic vascular resistances, +47 +/- 11 p. 100; wedged pulmonary arterial pressure, +44 +/- 15 p. 100. In conclusion, in patients with cirrhosis in a stable hemodynamic condition, intravenous administration of glypressin decreased portal venous pressure and blood flow into the superior portal systemic collateral circulation but did not prevent the untoward systemic hemodynamic effects of vasopressin.

UI MeSH Term Description Entries
D008103 Liver Cirrhosis Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules. Cirrhosis, Liver,Fibrosis, Liver,Hepatic Cirrhosis,Liver Fibrosis,Cirrhosis, Hepatic
D008236 Lypressin The porcine antidiuretic hormone (VASOPRESSINS). It is a cyclic nonapeptide that differs from ARG-VASOPRESSIN by one amino acid, containing a LYSINE at residue 8 instead of an ARGININE. Lys-vasopressin is used to treat DIABETES INSIPIDUS or to improve vasomotor tone and BLOOD PRESSURE. Lysine Vasopressin,Vasopressin, Lysine,8-Lysine Vasopressin,Diapid,Lys-Vasopressin,Lysyl Vasopressin,Postacton,8 Lysine Vasopressin,Lys Vasopressin,Vasopressin, 8-Lysine,Vasopressin, Lysyl
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005260 Female Females
D006439 Hemodynamics The movement and the forces involved in the movement of the blood through the CARDIOVASCULAR SYSTEM. Hemodynamic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077585 Terlipressin An inactive peptide prodrug that is slowly converted in the body to lypressin. It is used to control bleeding of ESOPHAGEAL VARICES and for the treatment of HEPATORENAL SYNDROME. Glipressin,Gly-Gly-Gly-8-Lys-vasopressin,Glycylpressin,Glypressin,N-(alpha)-glycyl-glycyl-glycyl-8-lysine vasopressin,Remestyp,TGLVP,Terlypressin,Triglycyl Lysine Vasopressin,Triglycyl-(8-lysine)vasopressin,Triglycylvasopressin,Vasopressin, tri-Gly-8-Lys-,Gly Gly Gly 8 Lys vasopressin,tri-Gly-8-Lys- Vasopressin
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

D Valla, and S S Lee, and R Moreau, and A Hadengue, and R Sayegh, and D Lebrec
July 1989, Journal of hepatology,
D Valla, and S S Lee, and R Moreau, and A Hadengue, and R Sayegh, and D Lebrec
January 1976, Digestion,
D Valla, and S S Lee, and R Moreau, and A Hadengue, and R Sayegh, and D Lebrec
January 1997, The Kurume medical journal,
D Valla, and S S Lee, and R Moreau, and A Hadengue, and R Sayegh, and D Lebrec
July 1971, American journal of surgery,
D Valla, and S S Lee, and R Moreau, and A Hadengue, and R Sayegh, and D Lebrec
January 1972, Review of surgery,
D Valla, and S S Lee, and R Moreau, and A Hadengue, and R Sayegh, and D Lebrec
December 1994, Internal medicine (Tokyo, Japan),
D Valla, and S S Lee, and R Moreau, and A Hadengue, and R Sayegh, and D Lebrec
January 1992, Drugs under experimental and clinical research,
D Valla, and S S Lee, and R Moreau, and A Hadengue, and R Sayegh, and D Lebrec
January 1988, Hepatology (Baltimore, Md.),
D Valla, and S S Lee, and R Moreau, and A Hadengue, and R Sayegh, and D Lebrec
February 1998, Hepatology (Baltimore, Md.),
D Valla, and S S Lee, and R Moreau, and A Hadengue, and R Sayegh, and D Lebrec
April 1996, Journal of hepatology,
Copied contents to your clipboard!